Aberrant erythropoiesis fuels tumor growth

Por Nakamura, Kyohei, Smyth, Mark J.
Publicado no Cell Res (2018)

TGFβ shuts the door on T cells

Por Bald, Tobias, Smyth, Mark J.
Publicado no Br J Cancer (2018)

Myeloid immunosuppression and immune checkpoints in the tumor microenvironment

Por Nakamura, Kyohei, Smyth, Mark J.
Publicado no Cell Mol Immunol (2019)

TREM2 marks tumor-associated macrophages

Por Nakamura, Kyohei, Smyth, Mark J.
Publicado no Signal Transduct Target Ther (2020)

The Relative Role of Lymphocyte Granule Exocytosis versus Death Receptor-Mediated Cytotoxicity in Viral Pathophysiology

Por Smyth, Mark J., Trapani, Joseph A.
Publicado em 1998

Immune surveillance of tumors

Por Swann, Jeremy B., Smyth, Mark J.
Publicado em 2007

NKT cell adjuvants in therapeutic vaccines against hematological cancers

Por Mattarollo, Stephen R., Smyth, Mark J.
Publicado em 2013

2018 Nobel Prize in physiology or medicine

Por Smyth, Mark J, Teng, Michele WL
Publicado no Clin Transl Immunology (2018)

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression

Por Smyth, Mark J, Teng, Michele W L
Publicado em 2014

Targeting immune checkpoints in hematological malignancies

Por Salik, Basit, Smyth, Mark J., Nakamura, Kyohei
Publicado no J Hematol Oncol (2020)

Fas Ligand-Mediated Lysis of Self Bystander Targets by Human Papillomavirus-Specific CD8(+) Cytotoxic T Lymphocytes

Por Smyth, Mark J., Krasovskis, Erika, Johnstone, Ricky W.
Publicado em 1998

DNAM-1: would the real natural killer cell please stand up!

Por Huntington, Nicholas D., Martinet, Ludovic, Smyth, Mark J.
Publicado no Oncotarget (2015)

Acquired resistance to immunotherapy and future challenges

Por Restifo, Nicholas P., Smyth, Mark J., Snyder, Alexander
Publicado no Nat Rev Cancer (2016)

α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

Por Hayakawa, Yoshihiro, Rovero, Stefania, Forni, Guido, Smyth, Mark J.
Publicado em 2003

A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas

Por Crowe, Nadine Y., Smyth, Mark J., Godfrey, Dale I.
Publicado em 2002

Hypoxia-driven immunosuppression contributes to the pre-metastatic niche

Por Sceneay, Jaclyn, Parker, Belinda S., Smyth, Mark J., Möller, Andreas
Publicado em 2013

The anticancer effects of HDAC inhibitors require the immune system

Por West, Alison C, Smyth, Mark J, Johnstone, Ricky W
Publicado em 2014

IFN type III: in vivo NK cell response

Por Souza-Fonseca-Guimaraes, Fernando, Young, Arabella, Smyth, Mark J.
Publicado no Oncotarget (2015)

Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer

Por Yan, Juming, Smyth, Mark J., Teng, Michele W.L.
Publicado no Cold Spring Harb Perspect Biol (2018)

Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity

Por Dougall, William C., Roman Aguilera, Amelia, Smyth, Mark J.
Publicado no Clin Transl Immunology (2019)